2016 HCV - Eliminating the Scourge

 

HCV-Scourge_Web_Banner_v1


HCV Scourge- Launch On Demand

About the Program

Program Overview

Chronic hepatitis C (CHC) afflicts millions of people in the United States.  It is a significant public health issue, because CHC can evolve into states that are associated with cirrhosis, hepatic fibrosis and hepatocellular carcinoma (HCC). The incidence of deaths from HCV infections is increasing, and, since 2007, the number of people who die from HCV infection in the United States each year has exceeded the numbers who die from HIV infection.  While significant progress has been made in the treatment of CHC, many clinicians with HCV infected patients are not aware of the full range of complex and emerging management and treatment options available or how to apply them to various patient scenarios.  Furthermore, infected patients are going undiagnosed due to lack of education and resources surrounding screening and diagnostic testing for CHC.  Due to the rapidly changing landscape of CHC management, these issues can significantly affect the treatment of patients with HCV infection and the quality of the care they receive, potentially affecting patient outcomes, increasing morbidity, mortality and treatment costs.  

This online program entitled, "Eliminating the HCV Scourge: Together We Can Do It," consists of case-based modules that feature a panel of HCV thought leaders who review and discuss the most critical aspects of HCV prevention, management and treatment.  Each presentation focuses on a different approach or population involved in HCV care.  The information and opinions provided are intended to improve a clinician's ability to prevent, diagnose and manage HCV infection.  Participants who complete these modules will gain increased understanding of the optimal management skills needed to treat various types of patients with CHC, which is expected to result in improved patient care, reduces morbidity and mortality, reduced costs and meaningful improvement in patient outcomes.

Back to Top

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be better able to:

  • Explain the long-term consequences of untreated CHC
  • Implement individualized antiviral treatment based on patient characteristics using available treatment options for patients with CHC
  • Develop optimal approaches for managing adverse events to facilitate adherence in patients being treated for CHC
  • Manage drug-drug interactions and other treatment issues experienced by patients with CHC patients and patients with HCV/HIV co-infection

Release Date: May 19, 2016

Expiration Date: May 19, 2017

Estimated time to complete each Module:  30-45 minutes

Media: Internet

Back to Top

Course Directors

Nezam H. Afdhal, MD
Professor of Medicine,
Harvard Medical School
Chief of Hepatology,
Director of Liver Center
Beth Israel Deaconess
Medical Center
Boston, Massachusetts
Mark Sulkowski, MD
Professor of Medicine and
Medical Director
Viral Hepatitis Center
Johns Hopkins University
School of Medicine
Baltimore, Maryland

 

Faculty

Brenda Appolo PA-C, MHS
Hepatology Physician Assistant
Physician Assistant /
Nurse Practitioner Manager
Division of Gastroenterology
University of Pennsylvania
Philadelphia, Pennsylvania
David E. Bernstein, MD, FACG
Chief Division of Hepatology and
Center for Liver Diseases
North Shore Long Island
Jewish Health Care System
Professor of Medicine
Hofstra North Shore-LIJ
School of Medicine
New York, New York
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Lennox Jeffers, MD
Chief of Hepatology
Miami VA Medical Center
Associate Chief
Center for Liver Disease,
Professor of Medicine
University of Miami’s
School of Medicine
Miami, Florida
Wilbert Jordan, MD
Medical Director
Charles Drew Medical Center
Los Angeles, California
Paul Kwo, MD
Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana
Alain H. Litwin, MD, MPH
Professor of Medicine
Professor of Clinical Psychiatry
& Behavioral Sciences
Albert Einstein College of Medicine
Montefior Medical Center
Bronx, New York
K. Rajender Reddy, MD
Ruimy Family President's Distinguished Professor of Medicine
Professor of Medicine in Surgery
Director of Hepatology
Director, Viral Hepatitis Center
University of Pennsylvania
Philadelphia, Pennsylvania 
Stacey B. Trooskin, MD, PhD
Assistant Professor
Division of Infectious Diseases
and HIV Medicine
Drexel University College of Medicine
Philadelphia, Pennsylvania

Back to Top

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Treating and Preventing HCV - DM and Obesity Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Treating and Preventing HCV - Intravenous Drug Users Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Treating and Preventing HCV - HCV/HIV Co-infection Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Treating and Preventing HCV - Genotype 4 Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

 

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

 

Brenda Appolo PA-C, MHS
  • Consulting Fees: BMS, Merck, Gilead
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents (e.g. speakers' bureaus): BMS, Merck, Gilead
Nezam Afdhal, MD
  • Consulting Fees: Merck, Gilead, Echosens, GSK, Ligand, Janssen, Roivant, Co-Crystal, Shionogi
  • Research Support: Gilead, Abbvie, BMS
  • Employee/Salary: Spring Bank Pharmaceuticals
  • Other: Director-TRIO Healthcare
  • Stock:Allurion, Gilead, Spring Bank Pharmaceuticals
David E. Bernstein, MD, FACG
  • Consulting Fees: Abbvie, Gilead, Merck
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents (e.g. speakers' bureaus): Abbvie, BMS, Gilead, Merck
  • Contracted Research: Abbvie, BMS, Gilead, Merck
Douglas Dieterich, MD
  • Consulting Fees: Gilead, BMS, AbbVie, Janssen
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents (e.g. speakers' bureaus): Gilead, BMS, AbbVie, Janssen
  • Contracted Research: Gilead, BMS, AbbVie, Janssen
Ian Frank, MD
  • Consulting Fees: Gilead
  • Contracted Research (to UPenn): ViiV, GSK
Paul Kwo, MD
  • Consulting Fees: Abbott, Abbvie, Quest, CVS, BMS, Gilead, Janssen, Merck, Alnylam
  • Contracted Research: Abbvie, BMS, Gilead, Janssen, Merck, Conatus, Esai
  • Other (DSMB): Inovio
Lennox Jeffers, MD
  • Nothing to Disclose
Wilbert Jordan, MD
  • Contracted Research: Gilead
Alain H. Litwin, MD, MPH
  • Consulting Fees: Gilead, Merck, Abbvie, BMS, Janssen
  • Contracted Research: Gilead, Merck
K. Rajender Reddy, MD
  • Consulting Fees: BMS, Gilead, Abbvie, Janssen, Merck
  • Contracted Research (To UPenn): BMS, Gilead, Abbvie, Janssen, Merck
Mark Sulkowski, MD
  • Contracted Research (to JHU): Abbvie, Gilead, Janssen, Merck
  • Consulting Fees: Abbvie, Crystal, Gilead, Janssen, Merck, Trek
Stacey B. Trooskin, MD, PhD
  • Consulting Fees: Gilead
  • Contracted Research: Gilead

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM planner and managers:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, RN, MSN, CHCP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

Back to Top

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. During the period, May 19, 2016 through May 19, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 11397 . Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

 

    PIM_small

 

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs

 

 

Back to Top

 

Prepare to print

Share this page:

Get link code to this page                     


Back to Top